Daniel A. Lawrence, Founder/Chairman of the Scientific Advisory Board

(HR)

<strong>Daniel A. Lawrence<br>Founder/Chairman of the Scientific Advisory Board <font align=”justify”></strong><br>Daniel A. Lawrence is the <a href=”http://mcircc.umich.edu/daniel-a-lawrence-phd/”>Frederick G. L. Huetwell Professor of Basic Research in Cardiovascular Medicine at the University of Michigan</a>, and a recognized world leader in serpin biology. He has published over 120 peer-reviewed articles, holds numerous patents in the field, and was awarded the prestigious 2010 International Society for Fibrinolysis and Proteolysis Prize. He has served as the Chair of the Plasminogen Activation &amp; Extracellular Proteolysis Gordon Conference, and Co-Chair of the Xth International Workshop on Molecular &amp; Cellular Biology of Plasminogen Activation.Professor Lawrence’s scientific career has focused on the impact of serpins in the pathology of vascular function and disease, where he has made significant discoveries. Dr. Lawrence was a member of the team that cloned and purified plasminogen activator inhibitor-1 (PAI-1), allowing its recognition as a member of the serpin family of structurally related proteins that inactivated proteases via a then unknown mechanism. He proceeded to study the serpin mechanism of action, and was the first to propose protease inhibition through distortion of the protease catalytic site by the transfer of free energy trapped in the serpin structure. Dr. Lawrence has pioneered research in advancing an understanding of how the unique molecular structure of serpins contributes to diseases as diverse as inflammation, fibrosis, and thrombosis, including being the first to identify a novel serpin target site that could potentially be exploited to pharmacologically regulate a variety of family members and functions. <a href=”https://scholar.google.com/citations?user=S3mvtCUAAAAJ&hl=en”>View Dr. Lawrence’s full publication list</a></font>